Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases by Kotecha, Rupesh & Ahluwalia, Manmeet
Baptist Health South Florida 
Scholarly Commons @ Baptist Health South Florida 
All Publications 
9-13-2021 
Impact of KRAS mutation status on the efficacy of 
immunotherapy in lung cancer brain metastases 
Rupesh Kotecha 
Baptist Health Medical Group; Miami Cancer Institute, rupeshk@baptisthealth.net 
Manmeet Ahluwalia 
Baptist Health Medical Group; Miami Cancer Institute, manmeeta@baptisthealth.net 
Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications 
Citation 
Scientific Reports (2021) 11(1) 
This Article -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health 
South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly 
Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net. 
1
Vol.:(0123456789)
Scientific Reports |        (2021) 11:18174  | https://doi.org/10.1038/s41598-021-97566-z
www.nature.com/scientificreports
Impact of KRAS mutation status 
on the efficacy of immunotherapy 
in lung cancer brain metastases
Adam Lauko1, Rupesh Kotecha2,3, Addison Barnett4, Hong Li5, Vineeth Tatineni6, 
Assad Ali4, Pradnya Patil7, Alireza M. Mohammadi1,4,8, Samuel T. Chao4,9, Erin S. Murphy4,9, 
Lilyana Angelov1,4,8, John H. Suh4,9, Gene H. Barnett1,4,8, Nathan A. Pennell7 & 
Manmeet S. Ahluwalia3,10*
Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer 
(NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases 
(NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICIs 
within 90 days of NSCLCBM diagnosis (ICI-90) and compared them to patients who never received ICIs 
(no-ICI). We reviewed 800 patients with LCBM who were diagnosed between 2010 and 2019 at a major 
tertiary care institution, 97% of whom received stereotactic radiosurgery (SRS) for local treatment 
of BM. OS from BM was compared between the ICI-90 and no-ICI groups using the Log-Rank test and 
Cox proportional-hazards model. Additionally, the impact of KRAS mutational status on the efficacy 
of ICI was investigated. After accounting for known prognostic factors, ICI-90 in addition to SRS led 
to significantly improved OS compared to no-ICI (12.5 months vs 9.1, p < 0.001). In the 109 patients 
who had both a known PD-L1 expression and KRAS status, 80.4% of patients with KRAS mutation had 
PD-L1 expression vs 61.9% in wild-type KRAS patients (p = 0.04). In patients without a KRAS mutation, 
there was no difference in OS between the ICI-90 vs no-ICI cohort with a one-year survival of 60.2% vs 
54.8% (p = 0.84). However, in patients with a KRAS mutation, ICI-90 led to a one-year survival of 60.4% 
vs 34.1% (p = 0.004). Patients with NSCLCBM who received ICI-90 had improved OS compared to no-ICI 
patients. Additionally, this benefit appears to be observed primarily in patients with KRAS mutations 
that may drive the overall benefit, which should be taken into account in the development of future 
trials.
Lung cancer is the most common primary tumor that metastasizes to the brain, accounting for approximately 
50% of brain metastases (BM)1. For patients without actionable mutations, systemic chemotherapy has shown 
little intracranial efficacy, and traditionally, non-small cell lung cancer (NSCLC) BM have been managed with 
local treatments, such as resection and radiotherapy.
Exciting developments in cancer therapeutics targeting the PD-1 or PD-L1 axis have led to the approval of 
multiple immune checkpoint inhibitors (ICIs) as standard of care options in the first line  setting2 and as salvage 
options after failure of first-line  chemotherapy3. However, given the historically poor prognosis of patients with 
NSCLCBM, these patients were excluded from many of the initial trials unless they had previously treated and 
stable intracranial  disease2–4. Recently, several retrospective series and a single center phase 2 clinical trial have 
demonstrated limited intracranial efficacy with ICIs alone, ranging from 12 to 40%5–7. Additionally, there is 
newer evidence that a combination approach with stereotactic radiosurgery (SRS) and ICI may be more beneficial 
for intracranial control, as this has been shown to have better intracranial response over either therapy  alone8. 
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Additionally, many researchers are interested in possible increased rates of the abscopal effect when fractional 
dose radiation and ICIs are given  concordantly9.
KRAS mutations are present in approximately 30% of NSCLC adenocarcinomas and have been associated 
with a poorer prognosis when compared to wild-type  tumors10–12. Until May 2021, there was no FDA approved 
targeted therapies towards KRAS mutations for patients with NSCLC. Patients frequently receive ICIs as standard-
of-care treatments based on PD-L1 expression, regardless of KRAS mutation status. There is also evidence that 
KRAS mutations lead to increased expression of PD-L1, a known predictor of response to  ICIs13,14; however, 
impact of KRAS mutation status on treatment outcome for patients with NSCLCBM has yet to be empirically 
demonstrated.
In this study, we analyzed a large population of patients with NSCLCBM who were treated at a single tertiary 
center. We compared the survival of those who received ICI after the diagnosis of BM to those who did not 
receive ICI within this timeframe. Additionally, the impact of KRAS mutation status on the efficacy of ICI was 
investigated. We hypothesized that patients treated with ICIs after the diagnosis of BM would have an improved 
survival and that within the ICI group, those with KRAS mutations would have improved survival over those 
with KRAS wild-type disease.
Methods
Patient selection and treatment. This retrospective cohort study included patients treated for 
NSCLCBM at a single tertiary care center from 2010 to 2019. This study was approved by the Cleveland Clinic 
Foundation institutional review board and received an informed consent waiver due to the retrospective nature 
of the study. All methods were carried out in accordance with relevant guidelines and regulations. Patient char-
acteristics, diagnostic information, and treatment details were abstracted from the shared electronic medical 
record.
All the patients’ treatments were extracted after diagnosis of the primary cancer. This included SRS, whole-
brain radiation therapy (WBRT), surgery, as well as any systemic therapies, including targeted therapies, chemo-
therapy, and ICI. Patients’ PD-L1 expression were extracted from pathology reports of tissue, primarily from 
the lung. Patients who had documented EGFR or ALK mutations who received a targeted therapy towards these 
mutations were excluded from this analysis. Patients who underwent resection of their intracranial tumors or 
diagnosed with small cell lung cancer were also excluded. All treatment decisions were made by the multidisci-
plinary team and were based on current national guideline standards at the time. Dosing schedule for Nivolumab 
was 3 mg/kg or 240 mg flat dose every other week and 2 mg/kg or 200 mg flat does every three weeks or 400 mg 
flat dose every six weeks for pembrolizumab.
Patients were divided into three groups based on if and when they were treated with ICIs. Those treated with 
ICIs within 90 days of the diagnosis of BM were classified as ICI-90, and those treated with ICI greater than 
90 days after diagnosis of BM were classified as G90. Patients who did not receive ICI after diagnosis of BM at 
any point were classified as no-ICI.
Outcome measures. Overall survival (OS) was determined from the date of diagnosis of BM until the 
date of death. Patients who were still alive at the day of collection or lost to follow-up were censored at the last 
follow-up date.
Statistical analysis. All variables included in this analysis had < 5% missing except for Karnofsky Perfor-
mance Status (KPS) at diagnosis (15% missing). Several numerical variables were also grouped as categorical and 
both their numerical and categorical forms were evaluated. This included age (< 65 and ≥ 65), number of SRS 
treatments (0–1 and ≥ 2) (only 3% of patients did not receive SRS), lesion number at diagnosis (1 and ≥ 2) and 
KPS (< 90 and ≥ 90). Patient demographic and clinical characteristics were compared using Chi-square test for 
categorical variables and Kruskal–Wallis test for numerical variables. If any differences between the three groups 
were detected, no-ICI and ICI-90 were then compared. Times from BM diagnosis to death or last contact were 
calculated for OS analysis. Patients who died after 2 years or followed more than 2 years were censored at 2 years.
Patient demographics and clinical characteristics that were potentially associated with OS (p < 0.05) among 
BM patients who did not have surgery were identified in univariate analysis using Kaplan–Meier method and 
simple Cox hazard models. Since identified factors potentially associated with OS were previously reported to 
associate with survival or commonly included in lung cancer BM  studies15, they were included in the multivari-
ate analysis of OS between ICI-90 and no ICI. A 1:1 propensity score (PS) matched analysis between no-ICI and 
ICI-90 was also performed to correct potential treatment selection biases. The matched pairs were identified from 
a logistic regression model with the Greedy method that included age, KPS, extracranial metastases (EC-mets), 
lesion number, and SRS number with exact match on EC-mets. Kaplan–Meier method was utilized to compare 
OS between matched ICI-90 and no-ICI group.
A secondary analysis explored ICI effect on OS by KRAS status. Among patients who had a known KRAS 
mutation status, Cox proportional hazard model with an ICI-KRAS interaction term was utilized to determine 
the impact of KRAS mutation status on ICI efficacy.
All analyses were performed using SAS version 9.4, two-sided p values are presented. A p < 0.05 was consid-
ered as statistically significant.
Results
Patient characteristics. A total of 800 patients were diagnosed with lung cancer BM at our tertiary center 
between 2010 and 2019. Ninety-seven percent of the patients in this cohort received SRS for intracranial treat-
ment of BM. One hundred and thirty-three patients with small cell lung cancer or NSCLC that was treated with 
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targeted therapy against an EGFR mutation or ALK translocations were excluded from the analysis, leaving 
667 patients. Additionally, 146 patients underwent an intracranial tumor resection, with four of these patients 
receiving ICIs versus 142 never receiving ICIs. Because of this heavily skewed distribution, these patients were 
excluded as well. This left 521 patients with the general characteristics outlined in Table 1. Twenty-five percent 
(n = 128) of patients received ICI greater than 90 days after the diagnosis of BM, 13% (n = 68) received ICI within 
90 days of diagnosis of BM, and 62% (n = 325) of patients never received ICI (Fig. 1).
Patient characteristics between those receiving ICI compared to those who never received ICI are outlined 
in Table 1. There was no statistical difference in age, sex, or race between the two groups (p > 0.05). The median 
KPS at diagnosis was 80 for both groups. The median number of lesions at the diagnosis of BM was 1 in no-ICI 
group and 2 in the ICI-90, however this variance was not statistically different (p = 0.27). Of the patients in the 
ICI-90 cohort, 55.2% had an EC-mets compared to only 44.0% in the no-ICI group.
Demographics and clinical factors that may associate with OS were first identified by univariate analysis 
across the 521 patients. KPS below 90 (p < 0.001), age older than 65 (p = 0.005), presence of EC-mets at diagno-
sis of BM (p = 0.02), adenocarcinoma histology (p < 0.001), and male sex (p = 0.02) were significant predictors 
of worse OS. However, the number of intracranial lesions at diagnosis of BM was not found to be statistically 
significant (p = 0.72) (Table 2).
ICI within 90 days. Overall survival from the time of diagnosis of BM was compared between those treated 
without ICI and those treated with ICI within the first 90 days. On univariable analysis, there was a significant 
difference in OS between the groups with median survival of 9.1 months and 12.5 months, respectively (p = 0.04) 
(Fig. 2A). In a multivariate analysis, treatment with ICI-90 led to significantly improved OS (p < 0.001) (Table 3). 
A similar analysis was performed excluding patients with missing KPS, and ICI-90 remained a significant pre-
dictor of OS (p = 0.001).
Additionally, a PS matching was performed to select patients who did not receive ICIs with similar character-
istics to the ICI-90 cohort. When both groups were matched to have similar age, KPS, EC-mets (exact match), 
number of lesions, and number of SRS treatments, there was almost a 5-month median survival advantage with 
ICIs within 90 days (12.5 vs 7.8 months, p = 0.005) (Fig. 2B).
Impact of KRAS mutation status on the efficacy of ICI. Given the emerging data regarding pres-
ence of KRAS mutation and response to ICI, we first analyzed the expression of PD-L1 based on KRAS muta-
tion status. Out of 800 total patients diagnosed with LCBM, 109 patients had both a known PD-L1 expression 
Table 1.  Patient characteristics at diagnosis of brain metastasis. Data not available for all subjects. Missing 
values: KPS = 80, lesion number = 2, srs number = 12, Histology = 19, Extracranial Metastases = 10. Statistics 
presented as Median [P25, P75] or N (column %). Significant differences (p < 0.05) are bolded.
Factor Total (N = 521) No-ICI (N = 325) ICI-90 (N = 68) G90 (N = 128)
p value overall/No-ICI vs 
IC-I90
Age 62.7 [56.9, 70.6] 63.0 [57.1, 70.7] 60.4 [54.1, 70.3] 62.2 [57.1, 70.3] 0.29
Age, ≥ 65 214 (41.1) 139 (42.8) 22 (32.4) 53 (41.4) 0.28
Sex: male 262 (50.3) 174 (53.5) 32 (47.1) 56 (43.8) 0.15
Race: white 439 (84.3) 272 (83.7) 55 (80.9) 112 (87.5) 0.43
KPS 80.0 [80.0, 90.0] 80.0 [70.0, 90.0] 80.0 [70.0, 90.0] 90.0 [80.0, 90.0] < 0.001/0.86
KPS ≥ 90 < 0.001
< 90 221 (42.4) 140 (43.1) 38 (55.9) 43 (33.6)
≥ 90 220 (42.2) 112 (34.5) 29 (42.6) 79 (61.7)
Unknown 80 (15.4) 73 (22.5) 1 (1.5) 6 (4.7)
Lesion number 2.0 [1.00, 3.0] 1.00 [1.00, 3.0] 2.0 [1.00, 3.0] 2.0 [1.00, 3.0] 0.27
Lesion ≥ 2 261 (50.3) 153 (47.4) 37 (54.4) 71 (55.5) 0.23
Number of SRS 1.00 [1.00, 2.0] 1.00 [1.00, 2.0] 1.00 [1.00, 2.0] 2.0 [1.00, 2.0] < 0.001/0.64
SRS ≥ 2 164 (32.2) 81 (25.7) 17 (25.4) 66 (52.0) < 0.001
Histology: adenocarcinoma 371 (73.9) 216 (70.6) 52 (76.5) 103 (80.5) 0.089
EC-mets 238 (46.6) 139 (44.0) 37 (55.2) 62 (48.4) 0.22
WBRT 131 (25.1) 86 (26.5) 11 (16.2) 34 (26.6) 0.19
KRAS status < 0.001/< 0.001
Negative 109 (20.9) 50 (15.4) 16 (23.5) 43 (33.6)
Positive 98 (18.8) 39 (12.0) 23 (33.8) 36 (28.1)
Missing 314 (60.3) 236 (72.6) 29 (42.6) 49 (38.3)
PDL1 status < 0.001/< 0.001
Negative 30 (5.8) 16 (4.9) 4 (5.9) 10 (7.8)
Positive 93 (17.9) 27 (8.3) 40 (58.8) 26 (20.3)
Missing 398 (76.4) 282 (86.8) 24 (35.3) 92 (71.9)
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and KRAS status. PD-L1 was expressed in 80.4% of patients with KRAS mutation vs. 61.9% of KRAS wild-type 
patients (p = 0.04).
We then compared OS from the time of BM between those not treated with ICIs vs. those treated with ICIs 
(Fig. 3). In patients without KRAS mutations, there was no statistical difference in OS between the ICI vs. no ICI 
cohorts with a one-year survival of 60.2% vs 54.8% (adjusted p = 0.84). However, in patients with KRAS mutations, 
patient treated with ICIs had a 1-year survival of 60.4% vs. 34.1% in the no-ICI cohort. On multivariate analysis 
including age, gender, SRS, histology, KPS, number of lesions, and presence of EC-mets, these results remained 
consistent and statistically significant (p = 0.004). When comparing all patients who received ICIs, there was no 
difference in OS from BM between patients with vs without KRAS mutations.
Discussion
Patients with NSCLCBM have a poor prognosis and traditional systemic chemotherapies have provided limited 
clinical benefit. With advances in targeted therapies and ICI, this dogma is beginning to shift dramatically. While 
some clinical data is available suggesting the efficacy of ICIs in patients with stable, asymptomatic brain metasta-
ses, there is almost no prospective or retrospective data in patients with progressive or symptomatic disease. Our 
study retrospectively analyzed patients treated for NSCLCBM at a single tertiary care center and compared those 
treated with ICIs to those who were not. In agreement with the clinical trials, we observed an improvement in 
OS when patients were treated with ICIs within 90 days of the diagnosis of brain metastases (p < 0.0001)2–4. This 
data suggests that ICIs provide an OS benefit over traditional chemotherapy or local therapy alone.
Surgery has long been a mainstay of BM treatment, however, advances in SRS have decreased its utilization. 
While investigating the prevalence of surgical resection was not the primary goal of this study, when we compared 
our ICI-90 cohort to our no-ICI cohort we found a large difference in the proportion who underwent resection of 
a BM (29.4% vs 5.7%, p < 0.001) and therefore we excluded these patients from the remaining analyses. Advances 
in SRS technology more readily allow for the targeting of multiple intracranial lesions, deep-seated tumors, in 
patients who are too frail for surgery, have multiple medical co-morbidities, and is also commonly used in the 
salvage  setting16,17. These improvements may account for the number of intracranial lesions not predicting OS 
within our cohort (hazard ratio of 0.99, p = 0.72). Newer prospective clinical trials are beginning to demonstrate 
that patients with multiple lesions can be treated with SRS and have improved intracranial  control18. Our cohort 
provides additional retrospective evidence that number of lesions may not influence OS when all lesions are 
treated with  SRS18,19. With that being said, other variables that have previously been reported, such as EC-mets, 
age and KPS all predicted  OS15,20.
In order to identify patient populations who respond best to ICIs, we investigated the impact of KRAS muta-
tion status. We found an improved OS in patients with a KRAS mutation who were treated with ICI within 90 days 
Figure 1.  Flow chart of the study population. ICI = immune checkpoint inhibitor; BM = Brain Metastases; 
LCBM = lung cancer brain metastases.
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Table 2.  Univariate analysis of demographics and clinical characteristics. Significant differences (p < 0.05) are 
bolded.
Variable N Events Median months 1-Year survival % (95% CI) log-rank p value
Cox univariate hazard ratio 
(95% CI) Cox univariate Wald p-value
Sex 0.023
Female 259 157 (61%) 13.4 58.4 (52.3, 64.5) –
Male 262 178 (68%) 11.1 48.6 (42.4, 54.8) 1.28 (1.03, 1.59) 0.024
Race 0.75
Non-white 82 51 (62%) 12.3 52.0 (40.9, 63.1) –
White 439 284 (65%) 12.7 53.8 (49.0, 58.5) 0.95 (0.71, 1.28) 0.75
Age 0.005
< 65 307 186 (61%) 13.8 56.8 (51.1, 62.4) –
≥ 65 214 149 (70%) 10.5 48.8 (42.0, 55.6) 1.36 (1.10, 1.69) 0.005
KPS < 0.001
< 90 221 157 (71%) 8.9 40.8 (34.2, 47.4) 1.97 (1.55, 2.50) < 0.001
≥ 90 220 119 (54%) 18.4 66.8 (60.5, 73.1) –
Missing 80 59 (74%) 12.1 51.3 (40.0, 62.6) 1.65 (1.21, 2.26) 0.002
Lesion number 0.49
1 258 160 (62%) 13.3 55.7 (49.4, 61.9) –
≥ 2 261 173 (66%) 12.3 51.4 (45.2, 57.6) 1.08 (0.87, 1.34) 0.49
SRS < 0.001
0–1 345 245 (71%) 9.8 43.4 (38.1, 48.8) –
≥ 2 164 82 (50%) 21.7 75.1 (68.4, 81.8) 0.45 (0.35, 0.58) < 0.001
Histology < 0.001
Other 131 100 (76%) 9.1 38.7 (30.1, 47.3) –
Adenocarcinoma 371 221 (60%) 15.0 58.4 (53.3, 63.5) 0.57 (0.45, 0.72) < 0.001
EC-mets 0.018
No 273 166 (61%) 13.9 57.7 (51.7, 63.6) –
Yes 238 162 (68%) 10.5 47.9 (41.4, 54.5) 1.30 (1.04, 1.61) 0.018
WBRT 0.11
No 390 248 (64%) 12.2 51.0 (45.9, 56.1) –
Yes 131 87 (66%) 14.9 60.7 (52.3, 69.1) 0.82 (0.64, 1.05) 0.11
Age 521 335 (64%) 12.7 53.5 (49.1, 57.8) 1.014 (1.003, 1.025) 0.012
KPS 441 276 (63%) 12.7 53.8 (49.1, 58.6) 0.96 (0.95, 0.97) < 0.001
Lesion number 519 333 (64%) 12.7 53.5 (49.1, 57.9) 0.99 (0.96, 1.03) 0.72
SRS 509 327 (64%) 12.7 53.8 (49.4, 58.2) 0.65 (0.57, 0.75) < 0.001
Figure 2.  (A) Overall survival comparing ICI-90 to no-ICI with the exclusion of patients who received surgery 
for brain metastases. (B) After a Greedy match was performed to balance the ICI-90 and no-ICI cohort after the 
removal of patients with intracranial surgery, overall survival from the diagnosis of brain metastases is graphed. 
Log-rank test was performed.
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Table 3.  Multivariate analysis on the effect of ICI within 90 days. Significant differences (p < 0.05) are bolded.
Variable N Events Cox multivariable hazard ratio (95% CI) Cox multivariable Wald p-value
ICI status
No-ICI 325 247 (76%) 1.87 (1.30, 2.68) < 0.001
ICI-90 68 39 (57%) –
Sex
Female 187 130 (70%) 1.02 (0.79, 1.32) 0.87
Male 206 156 (76%) –
Age
< 65 232 158 (68%) –
≥ 65 161 128 (80%) 1.302 (1.013, 1.674) 0.039
KPS
< 90 178 138 (78%) 1.69 (1.28, 2.23) < 0.001
≥ 90 141 93 (66%) –
Unknown 74 55 (74%) 0.93 (0.64, 1.34) 0.69
SRS
0–1 284 218 (77%) 2.08 (1.52, 2.85) < 0.001
≥ 2 98 60 (61%) –
Histology
Other 106 88 (83%) 1.39 (1.07, 1.82) 0.014
Adenocarcinoma 268 184 (69%) –
EC-mets
No 207 144 (70%) –
Yes 176 135 (77%) 1.31 (1.02, 1.68) 0.035
Lesion number
1 201 140 (70%) –
≥ 2 190 144 (76%) 1.38 (1.07, 1.78) 0.012
Figure 3.  Impact of KRAS status on efficacy of ICI. Overall survival is plotted from the start of ICIs. 
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over no-ICI. This difference was not observed in the patients with wild-type KRAS. A similar result was seen in 
a meta-analysis of three clinical trials that compared the difference in response to ICIs based on KRAS  status21. 
Additionally, another recently published study found that patients with KRAS mutations with advanced NSCLC 
had improved survival over patients with wild-type KRAS when treated with  ICI22. These findings suggest that 
while ICIs do not directly target KRAS protein, they may provide significant clinical benefit to these patients. 
Additionally, the development of KRAS targeted therapies opens the possibility for combination therapy with 
 ICIs23. KRAS mutation status should, therefore, be considered in the development of future clinical trials inves-
tigating ICIs and BM.
The retrospective nature of the study allows for errors in data collection from an electronic medical record 
not designed for research purposes. All our mutation and PD-L1 status was derived from the primary tumor 
and KRAS mutational subtypes were not collected. A 2015 study found that all patients with an activating KRAS 
mutation in the primary tumor shared this mutation in all clonally related  cases24. Additionally, another recent 
study found a 75.5% concordance between PD-L1 expression in primary tumor and BM suggesting that while 
PD-L1 status of primary tumor has some predictive value, changes in intracranially do  occur25. Additionally, 
although multivariable analysis was performed with known predictors of survival, the cohorts may have differed 
in other areas. We were unable to determine whether KRAS mutation status was an independent predictor of 
survival or if the increased PD-L1 expression in these patients accounts for the difference. The patients in the 
no-ICI group were not necessarily treated with any systemic chemotherapy and almost all received intracra-
nial SRS. Finally, while our study investigated OS after BM, we did not specifically investigate intracranial or 
extracranial response, allowing the possibility that any difference in OS may be due to control (or lack thereof) 
of extracranial disease.
This study reports a significant survival benefit of ICIs over chemotherapy or local control alone in patients 
with NSCLCBM. This retrospective analysis of patients treated for NSCLCBM has also emphasized the shift away 
from surgery for management of BM in the age of ICIs. Finally, our data suggests the greatest benefit of ICIs are 
seen in patients with KRAS mutations in their tumors, which should be considered in future trials.
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